Laszlo Radvanyi
11Patents
2h-index
19Co-inventors
47Inventor score
Filing activity: Jul 1, 2003 → Sep 10, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8207314B2 | Tumor antigens for prevention and/or treatment of cancer | Human Necessities | 13 | Active |
| US11141434B2 | Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof | Chemistry; Metallurgy | 3 | Active |
| US9512401B2 | B and T lymphocyte attenuator marker for use in adoptive T-cell therapy | Human Necessities | 2 | Active |
| US8021664B2 | Tumor antigens Bfa5 for prevention and/or treatment of cancer | Human Necessities | 1 | Expired |
| US7851213B2 | Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer | Chemistry; Metallurgy | 1 | Active |
| US7790857B2 | Monoclonal antibodies and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US8946174B2 | Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer | Chemistry; Metallurgy | 0 | Active |
| US11401506B2 | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy | Chemistry; Metallurgy | 0 | Active |
| US8802383B2 | Monoclonal antibodies and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US8361706B2 | Monoclonal antibodies and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12023355B2 | Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.